<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32024212</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Protective Immunity Elicited by VP1 Chimeric Antigens of Bacterial Ghosts against Hand-Foot-and-Mouth Disease Virus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">61</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines8010061</ELocationID><Abstract><AbstractText>This study was designed to evaluate the immunogenicity and protective efficacy of two VP1 chimeric antigens of bacterial ghosts. Inoculation of the two VP1 chimeric antigens of bacterial ghosts into BALB/c mice markedly elicited humoral and mucosal immune responses. The specific antibodies induced by the chimeric ghosts protected mice not only against the virus that causes hand-foot-and-mouth disease but also against <i>E.</i> <i>coli</i> O157:H7 bacterial infection. In comparison with the negative control, immunization with the chimeric ghosts protected mice against two LD<sub>50</sub> hand-foot-and-mouth disease viral infection. In addition, this specific immunity also protected the pups of pregnant mice immunized with the VP1 chimeric antigens of bacterial ghosts against 20 MLD <i>E.</i> <i>coli</i> <i>O157:H7</i> infection. Taken together, the results of this study verify for the first time that the VP1 chimeric antigens of bacterial ghosts are target candidates for a new type of vaccine against hand-foot-and-mouth disease. Additionally, this vaccine strategy also elicited a stronger immune response against <i>E.</i> <i>coli</i> O157:H7.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Saisai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yakun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Anhui Medical University, Hefei 230000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhili</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiajia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fanghong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Nianzhi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Deyan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Anhui Medical University, Hefei 230000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Fengtai District, Beijing 100071, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Anhui Medical University, Hefei 230000, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2018ZX10101003-005-001</GrantID><Agency>National Key Research Project</Agency><Country/></Grant><Grant><GrantID>31870156</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>SKLPBS1811</GrantID><Agency>National Key Lab Research program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackie virus</Keyword><Keyword MajorTopicYN="N">bacterial ghost</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">hand, foot, and mouth disease</Keyword></KeywordList><CoiStatement>The authors have no financial conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32024212</ArticleId><ArticleId IdType="pmc">PMC7158693</ArticleId><ArticleId IdType="doi">10.3390/vaccines8010061</ArticleId><ArticleId IdType="pii">vaccines8010061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang B., Li J., Wang Y., Du N., Sun L., Xiao H., Zhao Y., Bao W., Zhang W. Understanding the epidemiological characteristics of EV71 and CVA16 infection to aid the diagnosis and treatment of hand, foot, and mouth disease. J. Med Virol. 2019;91:201&#x2013;207. doi: 10.1002/jmv.25282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25282</ArticleId><ArticleId IdType="pubmed">30118553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathinayake P.S., Hsu A.C., Wark P.A. Innate immunity and immune evasion by enterovirus 71. Viruses. 2015;7:6613&#x2013;6630. doi: 10.3390/v7122961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7122961</ArticleId><ArticleId IdType="pmc">PMC4690884</ArticleId><ArticleId IdType="pubmed">26694447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.L., Cheng P.Y., Chin C.L., Huang L.M., Lin S.Y., Chiang B.L. Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine. Vaccine. 2018;36:4331&#x2013;4338. doi: 10.1016/j.vaccine.2018.05.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.090</ArticleId><ArticleId IdType="pubmed">29891349</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L.C., Kao C.M., Ling P., Su I.J., Chang T.M., Chen S.H. CD4 T-cell-independent antibody response reduces enterovirus 71 lethality in mice by decreasing tissue viral loads. Clin. Dev. Immunol. 2012;2012:580696. doi: 10.1155/2012/580696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/580696</ArticleId><ArticleId IdType="pmc">PMC3486008</ArticleId><ArticleId IdType="pubmed">23133489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet. Vaccines Ther. 2007;5:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford N.W., Graham S.M. EV71 vaccine: protection from a previously neglected disease. Lancet. 2013;381:1968&#x2013;1970. doi: 10.1016/S0140-6736(13)61124-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61124-1</ArticleId><ArticleId IdType="pubmed">23726163</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K.B., Lim B.K., Ye M.B., Chung S.Y., Nam J.H. A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response. Acta. Virologica. 2012;56:337&#x2013;342. doi: 10.4149/av_2012_04_337.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/av_2012_04_337</ArticleId><ArticleId IdType="pubmed">23237090</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Li Z., Zheng J., Yang L., Yu M., Yu H., Chen Y., Que Y., Shih J.W., et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics. 2014;4:498&#x2013;513. doi: 10.7150/thno.7457.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.7457</ArticleId><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte A., Wanner G., Sulzner M., Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch. Microbiol. 1992;157:381&#x2013;388. doi: 10.1007/BF00248685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00248685</ArticleId><ArticleId IdType="pubmed">1534215</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte A., Lubitz W. Biochemical characterization of phi X174-protein-E-mediated lysis of Escherichia coli. Eur. J. Biochem. 1989;180:393&#x2013;398. doi: 10.1111/j.1432-1033.1989.tb14661.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.1989.tb14661.x</ArticleId><ArticleId IdType="pubmed">2522390</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedmann E.M., Kyd J.M., Cripps A.W., Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines. 2007;6:241&#x2013;253. doi: 10.1586/14760584.6.2.241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.6.2.241</ArticleId><ArticleId IdType="pubmed">17408373</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao H., Yang H., Zhao D., Chen J., Zhang Q., Liang J., Yin Y., Kong G., Li G. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using ghosts as vector and adjuvant. Vaccine. 2018;36:4532&#x2013;4539. doi: 10.1016/j.vaccine.2018.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.06.006</ArticleId><ArticleId IdType="pubmed">29914847</ArticleId></ArticleIdList></Reference><Reference><Citation>Eko F.O., Schukovskaya T., Lotzmanova E.Y., Firstova V.V., Emalyanova N.V., Klueva S.N., Kravtzov A.L., Livanova L.F., Kutyrev V.V., Igietseme J.U., et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine. 2003;21:3663&#x2013;3674. doi: 10.1016/S0264-410X(03)00388-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(03)00388-8</ArticleId><ArticleId IdType="pubmed">12922096</ArticleId></ArticleIdList></Reference><Reference><Citation>Panthel K., Jechlinger W., Matis A., Rohde M., Szostak M., Lubitz W., Haas R. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun. 2003;71:109&#x2013;116. doi: 10.1128/IAI.71.1.109-116.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.71.1.109-116.2003</ArticleId><ArticleId IdType="pmc">PMC143412</ArticleId><ArticleId IdType="pubmed">12496155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai K., Tu W., Liu Y., Li T., Wang H. Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7. Sci. Rep. 2015;5:17479. doi: 10.1038/srep17479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep17479</ArticleId><ArticleId IdType="pmc">PMC4667225</ArticleId><ArticleId IdType="pubmed">26626573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 2015;60:797&#x2013;803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistor S., Hobom G. Expression of viral hemagglutinin on the surface of E. coli. Klin. Wochenschr. 1988;66:110&#x2013;116. doi: 10.1007/BF01774224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01774224</ArticleId><ArticleId IdType="pubmed">3280869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mader H.J., Szostak M.P., Hensel A., Lubitz W., Haslberger A.G. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine. 1997;15:195&#x2013;202. doi: 10.1016/S0264-410X(96)00141-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(96)00141-7</ArticleId><ArticleId IdType="pubmed">9066038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai K., Gao X., Li T., Hou X., Wang Q., Liu H., Xiao L., Tu W., Liu Y., Shi J., et al. Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response. Can. J. Microbiol. 2010;56:389&#x2013;398. doi: 10.1139/W10-025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/W10-025</ArticleId><ArticleId IdType="pubmed">20555401</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanghong C., Xiong L., Nan N., Zhan L., Nianzhi N., Deyan L., Hui W. VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment. Front. Immunol. 2019;10:2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856078</ArticleId><ArticleId IdType="pubmed">31787970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Yu S.L., Chen Y.T., Chen Y.H., Hsiao P.W., Chow Y.H., Chen J.R. The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus. PLoS One. 2019;14:e0210553. doi: 10.1371/journal.pone.0210553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210553</ArticleId><ArticleId IdType="pmc">PMC6334917</ArticleId><ArticleId IdType="pubmed">30650163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Wang J., Li B., Guo L., Li H., Song J., Yang Z., Li H., Fan H., Huang X., et al. Correction: A Novel Neutralizing Antibody Specific to the DE Loop of VP1 Can Inhibit EV-D68 Infection in Mice. J. Immunol. 2019;202:1905&#x2013;1906. doi: 10.4049/jimmunol.1801658.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1801658</ArticleId><ArticleId IdType="pubmed">30728214</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcher P., Mayr U.B., Azimpour-Tabrizi C., Eko F.O., Jechlinger W., Mayrhofer P., Alefantis T., Mujer C.V., DelVecchio V.G., Lubitz W. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev. Vaccines. 2004;3:681&#x2013;691. doi: 10.1586/14760584.3.6.681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.3.6.681</ArticleId><ArticleId IdType="pubmed">15606353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jechlinger W., Haller C., Resch S., Hofmann A., Szostak M.P., Lubitz W. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine. 2005;23:3609&#x2013;3617. doi: 10.1016/j.vaccine.2004.11.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.11.078</ArticleId><ArticleId IdType="pubmed">15855021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebensen T., Paukner S., Link C., Kudela P., de Domenico C., Lubitz W., Guzman C.A. Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol. 2004;172:6858&#x2013;6865. doi: 10.4049/jimmunol.172.11.6858.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.11.6858</ArticleId><ArticleId IdType="pubmed">15153504</ArticleId></ArticleIdList></Reference><Reference><Citation>Klose M., Jahnig F., Hindennach I., Henning U. Restoration of membrane incorporation of an Escherichia coli outer membrane protein (OmpA) defective in membrane insertion. J. Biol. Chem. 1989;264:21842&#x2013;21847.</Citation><ArticleIdList><ArticleId IdType="pubmed">2689448</ArticleId></ArticleIdList></Reference><Reference><Citation>Dornmair K., Kiefer H., Jahnig F. Refolding of an integral membrane protein. OmpA of Escherichia coli. J. Biol. Chem. 1990;265:18907&#x2013;18911.</Citation><ArticleIdList><ArticleId IdType="pubmed">2229053</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>